Amortisation is a number most investors skip, but it can shape reported profit. On the surface, it looks routine: A company spreads the cos...

Indian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...

Indian markets saw volatile trading on Thursday, closing nearly unchanged despite positive signals. Several companies including SBI, Titan,...

Crude oil prices and UAE's role in OPEC+ are influencing Indian markets. Experts suggest oil prices may fall in the medium term, easing con...

In India, appetite for weight-loss drugs is on the rise, with consumers increasingly turning to injectables such as Mounjaro and Ozempic fo...

Global demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...

"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...

India's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...

Gilead is making headlines with its planned acquisition of Tubulis GmbH, a Germany-based company, for a maximum of five billion dollars. Th...

Novo Nordisk is set to lower the price of its popular weight loss and diabetes drug, Ozempic. This move comes after several Indian drugmake...

Mankind Pharma is set to enter India's semaglutide market soon. The drug's patent expires this month, opening doors for new players. Mankin...

The Organisation of Pharmaceutical Producers of India (OPPI) is requesting exemptions for patented and orphan drugs from government price c...

With Novartis losing patent protection for Vildagliptin in December, the cost of therapy is expected to reduce by over 50%.

The patent expiry of several major 'blockbuster' drugs, coupled with other factors, will fuel growth of global generic pharmaceuticals mark...

Patent expiry will be a major avenue of growth for the Indian pharmaceutical industry as products worth $235 billion are going off patent w...

Glenmark Pharmaceuticals’ patent challenge against Schering Plough’s cholesterol-lowering drug Zetia will come up for hearing in the US dis...